| Abstrakt: |
Background: Psoriasis is a chronic inflammatory skin disorder with significant impact on quality of life. The evolving landscape of treatment modalities includes traditional therapies and newer biologic agents. This study systematically reviews the efficacy and safety of various psoriasis treatments to guide clinical decision-making. Methods: A comprehensive literature search was conducted across PubMed, Embase, Cochrane Library, and ClinicalTrials.gov, yielding 45 studies that met the inclusion criteria. These studies were categorized into four treatment groups: topical, phototherapy, systemic, and biologic therapies. Data on efficacy, measured by PASI score reduction, and safety were extracted and analyzed. Results: Biologic therapies targeting TNF-α, IL-12/23, and IL-17 demonstrated the highest efficacy with mean PASI reductions of 75%, 72%, and 78%, respectively. Systemic therapies such as methotrexate and cyclosporine showed mean PASI reductions of 65% and 70%. Topical treatments and phototherapy also proved effective but were less impactful compared to biologics. Safety profiles varied, with biologics associated with increased risk of infections and injection site reactions, while systemic therapies had notable risks of organ toxicity. Conclusion: Biologic therapies represent a significant advancement in psoriasis management, offering superior efficacy for moderate to severe cases. However, their high cost and potential side effects highlight the need for personalized treatment approaches. Traditional therapies remain valuable, particularly for milder forms or as adjunctive treatments. Future research should focus on long-term safety and efficacy, and strategies to optimize treatment outcomes. [ABSTRACT FROM AUTHOR] |
